Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0345904 (liver cancer)
 15,188 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Diethylnitrosamine (DEN) was applied orally to a total of 250 female Wistar rats in a single dose (d) of 3 mg/kg body weight 5 times a week for a duration of 20 weeks. After approximately 150 days exploratory laparotomy was performed to all animals. By inspection of the liver they were divided into 4 stages of disease according to the extent of cancer formation. The reaction of rats with DEN induced liver tumors was tested using a 4-drug combination chemotherapy with different equitoxic doses of Adriamycin (Adm), Methotrexate (Mtx), 5-Fluorouracil (5-FU) and Cyclophosphamide (CP). No benefit of drug treatment could be noted. In drug treated animals no decrease in the development of the liver tumors, in the frequency of metastases nor in the frequency of tumors of other origin could be demonstrated. The parallels of chemotherapy in chemically induced liver cancer to clinical experience are discussed.
 ...
PMID:Chemotherapy studies in autochthonous rat tumors: hepatomas. 20 2

One hundred and sixty-eight patients with unresectable primary liver cancer were prospectively studied by members of the Eastern Cooperative Oncology Group. These patients were randomized to receive treatment with oral 5-Fluorouracil (5FU), oral 5-Fu plus Streptozotocin, oral 5-Fu plus Methyl-CCNU or Adriamycin. The single agent treatments (oral 5-Fu and Adriamycin) were associated with less gastrointestinal toxicity than were the oral 5-Fu treatment combinations. A total of 15 partial responses were reported. Adriamycin appears to be the most active agent and responsible for 9 of the 15 responses. No response was seen in any of the 48 patients randomized to oral 5-Fu alone. The survival associated with oral 5-Fu alone was significantly shorter than the survival time associated with the remaining 3 treatment programs among both North American and South African patients. A multivariate model of survival was formulated. Covariates of prognostic significance were treatment, initial performance status and sex. South African black patients had a shorter survival time than North American black patients. Excluding oral 5-Fu from consideration, prognostic variables appeared to dominate any differences between the remaining treatments under study.
 ...
PMID:Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. 21 18

The survival of 47 patients with liver malignancies treated with continuous portal infusion of fluorouracil (5-FU) has been studied. 18 of them had been treated initially by hepatic artery ligation. Total mean survival was 9.4 months. Patients treated with hepatic artery ligation + 5-FU lived longer (mean 10.8 months) than those treated with 5-FU alone (7.4 months). The survival was longer than could be expected for patients treated for primary liver cancer or for liver metastases from colo-rectal cancer, when compared with the "untreated" group. It is concluded that continuous portal infusion of 5-FU appears to prolong survival in some groups of patients with malignant liver tumours. However, the influence of "unspecific, general" therapy is difficult to evaluate.
 ...
PMID:Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer. 103 74

The survival of 47 patients with liver malignancies treated with continuous portal infusion of fluorouracil (5-FU) has been studied. 18 of them had been treated initially by hepatic artery ligation. Total mean survival was 9.4 months. Patients treated with hepatic artery ligation + 5-FU lived longer (mean 10.8 months) than those treated with 5-FU alone (7.4 months). The survival was longer than could be expected for patients treated for primary liver cancer or for liver metastases from colo-rectal cancer, when compared with the "untreated" group. It is concluded that continuous portal infusion of 5-FU appears to prolong survival in some groups of patients with malignant liver tumours. However, the influence of "unspecific, general" therapy is difficult to evaluate.
 ...
PMID:Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer. 126 5

SF-SP capsules, containing sustained release granules of tegafur, were given to 17 patients with liver cancer (5 primary and 12 metastatic), and tissue levels of tegafur and its metabolites, inhibition of thymidylate synthetase were examined. 5-FU and FdUMP, the active metabolites of tegafur, showed a good accumulation in hepatic lesion and their levels were found to be higher in patients with primary lesion than in metastatic one. In contrast, inhibitory rate of thymidylate synthetase in metastatic lesion was larger than in primary one, suggesting that the agent has stronger antitumor effect against metastatic lesion. This result is consistent with our clinical experiences. No clear relationship between tissue level of tegafur or its metabolites and inhibitory rate of thymidylate synthetase was found. Inhibition of DNA synthesis and/or RNA function are thought to be the action mechanisms of 5-FU and its derivatives. The present study suggests that measurement of the inhibition of thymidylate synthetase in malignant tissue together with the concentration of the drug and its metabolites may contribute for the elucidation of the antitumor effect of the drug.
 ...
PMID:[Pharmacokinetic study of tegafur in the hepatic tissue obtained from the patients with liver cancer]. 158 Jun 40

We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy. A 70-year-old male with rectosigmoid carcinoma was admitted to our hospital. Abdominal CT and echography revealed solid mass in the liver. He underwent low anterior resection and infuse-a-port was inserted because of arterial infusion chemotherapy for metastatic liver cancer. 5-FU (250 mg per day) was infused continuously and MMC at the dose of 8 mg for one time in a week was administered. Two months later, hepatic tumor disappeared and the serum CEA level also normalized. At this writing, the patient is alive and well and complete remission has been obtained for more than 10 months.
 ...
PMID:[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy]. 158 Jun 47

Seventy transcatheter hepatic artery chemoembolizations with an emulsion containing iodized oil, adriamycin and 5-Fu were undertaken for the treatment of primary liver cancer in 58 patients and secondary liver cancer in 2 patients. The oil emulsion was selectively lodged in tumor vessels and small daughter nodules not detected by angiography or computed tomography prior to the chemoembolization Following the procedure, liver tumors appeared as areas of markedly high density on CT Hepatectomy performed on 3 of these cases following the chemoembolization found complete necrosis of the tumor in 2. The cumulative one-and two-year survival rates were 35.5% and 24.1% respectively. The results we have got indicate that the chemoembolization is a useful palliative measure for the treatment of hepatic neoplasms.
 ...
PMID:[Transcatheter hepatic artery chemoembolization in the treatment of liver cancer]. 237 35

Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy. The histological types were hepatoblastoma and hepatocellular carcinoma, 3 cases respectively. The clinical stages were 1 recurrent case in I, 1 in IIIA, 2 in IIIB and 2 in IV. Seldinger method and cannulation at laparotomy were employed in 4 cases and 2 cases, respectively. In the eldest case, a catheter with dual lumen reservoir developed in our department was inserted, making it possible to infuse drugs into hepatic artery and cutting off hepatic arterial blood flow temporarily. The anticancer drug used was ADM, CDDP, 5-FU, THP-ADM, and MMC; antiAFP-anticancer drug conjugate missile therapy was employed in 4 cases. According to image diagnosis, reduction or necrosis of tumor was observed in 5 cases. In all cases, AFP scores decreased. In 5 dead cases, 4 cases died of tumor enlargement (average survival time 16.3 months); 1 case died of DIC during chemotherapy. The other case could eventually undergo complete resection and is now alive. Intra-arterial infusion therapy seemed to be useful for patients of infant unresectable hepatic cancer.
 ...
PMID:[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children]. 247 63

Fifty-nine colorectal cancer patients with metastatic liver cancer who underwent intra-arterial infusion chemotherapy (IAIC) at the National Cancer Center Hospital from May 1986 to February 1989 were reviewed. Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer. Catheter troubles, including severe infection (8), extravasations (3), obstruction (1) and other problems (1) occurred in 13 (22.0%) patients, and 6 patients (10.2%) were unable to receive IAIC. Three patients did not undergo IAIC because of hepatitis or other reasons. Serious complications following IAIC, including sclerosing cholangitis (6), extravasations (6) and obstructions (3) were observed in 15 patients (30.0%). Results of IAIC were discussed in 21 patients undergoing hepatic resection and 17 patients with nonresectable metastatic liver cancer. 5-Fluorouracil (5-FU) (700 mg/m2) and mitomycin C (MMC) (7 mg/m2) were infused through implantable pumps every week or every two weeks. Total infused doses of 5-FU ranged from 500 to 15,000 mg (mean: 8,300 +/- 3,400 mg) and those of MMC were from 26 to 144 mg (mean: 58.8 +/- 32.7 mg) in 21 patients undergoing hepatic resections, whereas 1,500-26,250 mg (mean: 11,000 +/- 7,800 mg) of 5-FU and 0-130 mg of MMC (mean: 57.3 +/- 33.3) were infused in 17 patients with nonresectable liver cancer. Seven patients (33.3%) had recurrent liver cancer during 7-31 months (mean: 16.2 +/- 6.0 m) follow-up after hepatic resections, whilst only 3 of 13 patients (23.1%) with solitary liver metastasis had recurrent liver cancer. Three of these recurrent liver cancer patients (37.5%) underwent hepatic re-excision. Seven of 17 nonresectable patients (41.2%) were responders. Three patients completely responded (CR) and 4 responded partially (PR). Another study is needed to clarify the effect of IAIC in survival. IAIC should be undertaken as a treatment not only for patients with nonresectable metastatic liver cancer, but also for those with resectable metastatic liver cancer in order to prevent hepatic recurrence.
 ...
PMID:[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. 250 27

Seven cases of liver cancer with replaced right hepatic artery were treated with arterial infusion therapy using implanted reservoir. The reservoir was surgically implanted in all cases. In 5 cases, right hepatic artery ligation was done simultaneously. TAE via right hepatic artery and ligation of middle and left hepatic artery was done in 2 other cases. ADM, CDDP, MMC, 5-FU and Lentinan were used. As the result, decrease in tumor size or necrosis of tumor was found in 3 cases of hepatomas, necrosis of tumor was found in 1 of three cases of metastatic liver cancer and remarkable decrease in tumor size and normalization of CEA level were found in another case. Arterial infusion therapy using implanted reservoir for the cases with variation would be effective with the combination of hepatic ligation or TAE.
 ...
PMID:[Reservoir implanted arterial infusion therapy in liver cancer with replaced right hepatic artery]. 250 33


1 2 3 4 5 6 7 8 9 10 Next >>